• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·GODAVARI.BO
Share

Godavari Drugs Limited Stocks

₹ 109Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 9.24M

₹ 109
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Godavari Drugs Ltd. engages in the manufacture of active pharmaceutical ingredients and its intermediates. Its products include Ciprofloxacin Hydrochloride, Enrofloxacin, Centrizine Hydrochloride, Ethambutol Hydrochloride, A D Lactone, and Benzhyryl Piperazine. The company was founded on December 2, 1987 and is headquartered in Secunderabad, India.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair val

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 01:08

The assets of the "AI-Nostradamus" fund fell to $10 billion following the sale of part of its portfolio

30.07.2026 23:45

OpenAI has lowered the price of GPT-5.6 for budget-conscious customers

30.07.2026 23:38

UEFA has threatened to boycott FIFA tournaments over plans to sell World Cup rights to investors

30.07.2026 23:35

The yuan rose to its highest level since 2023 amid a decline in the dollar following the Fed meeting

30.07.2026 22:48

SpaceX has been awarded a $1.6 billion contract by the U.S. Space Force

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026